Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Scalp hair cortisol and testosterone levels in patients with sarcoidosis.

van Manen MJG, Wester VL, van Rossum EFC, van den Toorn LM, Dorst KY, de Rijke YB, Wijsenbeek MS.

PLoS One. 2019 Jun 14;14(6):e0215763. doi: 10.1371/journal.pone.0215763. eCollection 2019.

2.

Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis.

Glassberg MK, Wijsenbeek MS, Gilberg F, Petzinger U, Kirchgaessler KU, Albera C.

Eur Respir J. 2019 Jun 4. pii: 1900399. doi: 10.1183/13993003.00399-2019. [Epub ahead of print] No abstract available.

PMID:
31164431
3.

Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.

Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Moran D, Santin-Janin H, Aubin F, Mulder GJ, Gupta R, Richeldi L.

Lancet Respir Med. 2019 May 17. pii: S2213-2600(19)30172-9. doi: 10.1016/S2213-2600(19)30172-9. [Epub ahead of print]

PMID:
31122893
4.

Feasibility of a Comprehensive Home Monitoring Program for Sarcoidosis.

Moor CC, Gür-Demirel Y, Wijsenbeek MS.

J Pers Med. 2019 May 5;9(2). pii: E23. doi: 10.3390/jpm9020023.

5.

Comprehensive Supportive Care for Patients with Fibrosing Interstitial Lung Disease.

Wijsenbeek MS, Holland AE, Swigris JJ, Renzoni EA.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):152-159. doi: 10.1164/rccm.201903-0614PP. No abstract available.

PMID:
31051080
6.

Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials.

Wuyts W, Antin-Ozerkis D, Huggins JT, LaCamera PP, Spagnolo P, Vašáková M, Wijsenbeek MS, Polman B, Kirchgaessler KU, Scholand MB.

Respir Med. 2019 Apr;150:120-125. doi: 10.1016/j.rmed.2019.02.021. Epub 2019 Mar 13.

7.

First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative.

Kampstra NA, Grutters JC, van Beek FT, Culver DA, Baughman RP, Renzoni EA, Wuyts W, Kouranos V, Wijsenbeek MS, Biesma DH, van der Wees PJ, van der Nat PB.

BMJ Open Respir Res. 2019 Feb 18;6(1):e000394. doi: 10.1136/bmjresp-2018-000394. eCollection 2019.

8.

Research highlights from the 2018 ERS International Congress: interstitial lung diseases.

Alfaro TM, Moor CC, Alfieri V, Jeny F, Kreuter M, Wijsenbeek MS, Renzoni EA, Bargagli E, Nunes H, Spagnolo P, Bonella F, Molina-Molina M, Antoniou K, Poletti V.

ERJ Open Res. 2019 Feb 18;5(1). pii: 00215-2018. doi: 10.1183/23120541.00215-2018. eCollection 2019 Feb. Review.

9.

The impact of the new Global Lung Function Initiative T LCO reference values on trial inclusion for patients with idiopathic pulmonary fibrosis.

Wapenaar M, Miedema JR, Lammering CJ, Mertens FW, Wijsenbeek MS.

Eur Respir J. 2019 Jan 31;53(2). pii: 1801895. doi: 10.1183/13993003.01895-2018. Print 2019 Feb. No abstract available.

PMID:
30760543
10.

Inflammation and immunity in IPF pathogenesis and treatment.

Heukels P, Moor CC, von der Thüsen JH, Wijsenbeek MS, Kool M.

Respir Med. 2019 Feb;147:79-91. doi: 10.1016/j.rmed.2018.12.015. Epub 2019 Jan 9. Review.

PMID:
30704705
11.

Targeting interleukin-13 in idiopathic pulmonary fibrosis: from promising path to dead end.

Wijsenbeek MS, Kool M, Cottin V.

Eur Respir J. 2018 Dec 13;52(6). pii: 1802111. doi: 10.1183/13993003.02111-2018. Print 2018 Dec. No abstract available.

PMID:
30545962
12.

Validity of the Patient Experiences and Satisfaction with Medications (PESaM) Questionnaire.

Kimman ML, Wijsenbeek MS, van Kuijk SMJ, Wijnsma KL, van de Kar NCAJ, Storm M, van Jaarsveld X, Dirksen CD; PESaM Collaborating Group.

Patient. 2019 Feb;12(1):149-162. doi: 10.1007/s40271-018-0340-6.

13.

Needs, Perceptions and Education in Sarcoidosis: A Live Interactive Survey of Patients and Partners.

Moor CC, van Manen MJG, van Hagen PM, Miedema JR, van den Toorn LM, Gür-Demirel Y, Berendse APC, van Laar JAM, Wijsenbeek MS.

Lung. 2018 Oct;196(5):569-575. doi: 10.1007/s00408-018-0144-4. Epub 2018 Aug 7.

14.

A home monitoring program including real-time wireless home spirometry in idiopathic pulmonary fibrosis: a pilot study on experiences and barriers.

Moor CC, Wapenaar M, Miedema JR, Geelhoed JJM, Chandoesing PP, Wijsenbeek MS.

Respir Res. 2018 May 29;19(1):105. doi: 10.1186/s12931-018-0810-3.

15.

Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.

Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Santin-Janin H, Mulder GJ, Bartholmai B, Gupta R, Richeldi L.

JAMA. 2018 Jun 12;319(22):2299-2307. doi: 10.1001/jama.2018.6129.

16.

Fibrocytes are increased in lung and peripheral blood of patients with idiopathic pulmonary fibrosis.

Heukels P, van Hulst JAC, van Nimwegen M, Boorsma CE, Melgert BN, van den Toorn LM, Boomars KAT, Wijsenbeek MS, Hoogsteden H, von der Thüsen JH, Hendriks RW, Kool M, van den Blink B.

Respir Res. 2018 May 10;19(1):90. doi: 10.1186/s12931-018-0798-8.

17.

Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes.

Broos CE, Koth LL, van Nimwegen M, In 't Veen JCCM, Paulissen SMJ, van Hamburg JP, Annema JT, Heller-Baan R, Kleinjan A, Hoogsteden HC, Wijsenbeek MS, Hendriks RW, van den Blink B, Kool M.

Eur Respir J. 2018 Mar 1;51(3). pii: 1701124. doi: 10.1183/13993003.01124-2017. Print 2018 Mar.

PMID:
29449421
18.

Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis.

Broos CE, Wapenaar M, Looman CWN, In 't Veen JCCM, van den Toorn LM, Overbeek MJ, Grootenboers MJJH, Heller R, Mostard RL, Poell LHC, Hoogsteden HC, Kool M, Wijsenbeek MS, van den Blink B.

Eur Respir J. 2018 Jan 18;51(1). pii: 1702089. doi: 10.1183/13993003.02089-2017. Print 2018 Jan. No abstract available.

19.

Development and feasibility of an eHealth tool for idiopathic pulmonary fibrosis.

Moor CC, van Manen MJG, Tak NC, van Noort E, Wijsenbeek MS.

Eur Respir J. 2018 Mar 29;51(3). pii: 1702508. doi: 10.1183/13993003.02508-2017. Print 2018 Mar. No abstract available.

PMID:
29348156
20.

Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis.

Moor CC, Heukels P, Kool M, Wijsenbeek MS.

Front Med (Lausanne). 2017 Dec 20;4:226. doi: 10.3389/fmed.2017.00226. eCollection 2017. Review.

21.

Th17-lineage cells in pulmonary sarcoidosis and Löfgren's syndrome: Friend or foe?

Miedema JR, Kaiser Y, Broos CE, Wijsenbeek MS, Grunewald J, Kool M.

J Autoimmun. 2018 Feb;87:82-96. doi: 10.1016/j.jaut.2017.12.012. Epub 2018 Jan 5. Review.

PMID:
29310925
22.

Clubbing in patients with fibrotic interstitial lung diseases.

van Manen MJG, Vermeer LC, Moor CC, Vrijenhoeff R, Grutters JC, Veltkamp M, Wijsenbeek MS.

Respir Med. 2017 Nov;132:226-231. doi: 10.1016/j.rmed.2017.10.021. Epub 2017 Nov 2.

PMID:
29229102
23.

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.

Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U.

Eur Respir Rev. 2017 Dec 6;26(146). pii: 170057. doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31. Review.

24.

No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis.

Broos CE, Poell LHC, Looman CWN, In 't Veen JCCM, Grootenboers MJJH, Heller R, van den Toorn LM, Wapenaar M, Hoogsteden HC, Kool M, Wijsenbeek MS, van den Blink B.

Respir Med. 2018 May;138S:S31-S37. doi: 10.1016/j.rmed.2017.10.022. Epub 2017 Oct 31.

PMID:
29137908
25.

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis.

van Manen MJG, Birring SS, Vancheri C, Vindigni V, Renzoni E, Russell AM, Wapenaar M, Cottin V, Wijsenbeek MS.

Eur Respir J. 2017 Oct 19;50(4). pii: 1701157. doi: 10.1183/13993003.01157-2017. Print 2017 Oct. No abstract available.

26.

A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.

Birring SS, Wijsenbeek MS, Agrawal S, van den Berg JWK, Stone H, Maher TM, Tutuncu A, Morice AH.

Lancet Respir Med. 2017 Oct;5(10):806-815. doi: 10.1016/S2213-2600(17)30310-7. Epub 2017 Sep 8.

27.

Patient and partner empowerment programme for idiopathic pulmonary fibrosis.

van Manen MJG, van 't Spijker A, Tak NC, Baars CT, Jongenotter SM, van Roon LR, Kraan J, Hoogsteden HC, Wijsenbeek MS.

Eur Respir J. 2017 Apr 26;49(4). pii: 1601596. doi: 10.1183/13993003.01596-2016. Print 2017 Apr. No abstract available.

28.

What patients with pulmonary fibrosis and their partners think: a live, educative survey in the Netherlands and Germany.

van Manen MJ, Kreuter M, van den Blink B, Oltmanns U, Palmowski K, Brunnemer E, Hummler S, Tak NC, van den Toorn L, Miedema J, Hoogsteden HC, Wijsenbeek MS.

ERJ Open Res. 2017 Feb 14;3(1). pii: 00065-2016. doi: 10.1183/23120541.00065-2016. eCollection 2017 Jan.

29.

Optimizing quality of life in patients with idiopathic pulmonary fibrosis.

van Manen MJ, Geelhoed JJ, Tak NC, Wijsenbeek MS.

Ther Adv Respir Dis. 2017 Mar;11(3):157-169. doi: 10.1177/1753465816686743. Epub 2017 Jan 1. Review. Erratum in: Ther Adv Respir Dis. 2017 Jun;11(6):245.

30.

[A rare form of obstructive pulmonary disease].

van Loenhout CJ, den Bakker MA, van Wijsenbeek MS, Hoek RA, van Hal PT.

Ned Tijdschr Geneeskd. 2016;160:D757. Dutch.

PMID:
28074734
31.

Translation and validation of the King's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch.

Wapenaar M, Patel AS, Birring SS, Domburg RTV, Bakker EW, Vindigni V, Sköld CM, Cottin V, Vancheri C, Wijsenbeek MS.

Chron Respir Dis. 2017 May;14(2):140-150. doi: 10.1177/1479972316674425. Epub 2016 Dec 26.

32.

Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns.

Kreuter M, Wijsenbeek MS, Vasakova M, Spagnolo P, Kolb M, Costabel U, Weycker D, Kirchgaessler KU, Maher TM.

Eur Respir J. 2016 Nov;48(5):1524-1526. doi: 10.1183/13993003.01482-2016. No abstract available.

33.

Cough in idiopathic pulmonary fibrosis.

van Manen MJ, Birring SS, Vancheri C, Cottin V, Renzoni EA, Russell AM, Wijsenbeek MS.

Eur Respir Rev. 2016 Sep;25(141):278-86. doi: 10.1183/16000617.0090-2015. Review.

34.

Acetylcysteine in IPF: the knockout blow?

Wijsenbeek MS, Collard HR.

Lancet Respir Med. 2016 Jun;4(6):420-1. doi: 10.1016/S2213-2600(16)30085-6. Epub 2016 May 5. No abstract available.

PMID:
27161256
35.

Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis.

Kreuter M, Wijsenbeek MS, Vasakova M, Spagnolo P, Kolb M, Costabel U, Weycker D, Kirchgaessler KU, Maher TM.

Eur Respir J. 2016 Jun;47(6):1776-84. doi: 10.1183/13993003.02087-2015. Epub 2016 Apr 21. Erratum in: Eur Respir J. 2016 Aug;48(2):593.

36.

Validation of the King's Sarcoidosis Questionnaire (KSQ) in a Dutch sarcoidosis population.

Van Manen MJ, Wapenaar M, Strookappe B, Drent M, Elfferich M, de Vries J, Gosker HR, Birring SS, Patel AS, van den Toorn L, van den Blink B, Boomars K, Hoitsma E, Wijsenbeek MS.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Mar 29;33(1):75-82.

PMID:
27055839
37.

Treatment of Sarcoidosis.

Wijsenbeek MS, Culver DA.

Clin Chest Med. 2015 Dec;36(4):751-67. doi: 10.1016/j.ccm.2015.08.015. Review.

PMID:
26593147
38.

Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis.

Wijsenbeek MS, Grutters JC, Wuyts WA.

Adv Ther. 2015 Jul;32(7):691-704. doi: 10.1007/s12325-015-0225-1. Epub 2015 Jul 15.

39.

[Idiopathic pulmonary fibrosis: new insights].

Kraan JW, van den Blink B, van den Toorn LM, Bresser P, van Beek FT, Grutters JC, Wijsenbeek MS.

Ned Tijdschr Geneeskd. 2015;159:A8148. Review. Dutch.

PMID:
25654681
40.

Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.

Judson MA, Baughman RP, Costabel U, Drent M, Gibson KF, Raghu G, Shigemitsu H, Barney JB, Culver DA, Hamzeh NY, Wijsenbeek MS, Albera C, Huizar I, Agarwal P, Brodmerkel C, Watt R, Barnathan ES.

Eur Respir J. 2014 Nov;44(5):1296-307. doi: 10.1183/09031936.00000914. Epub 2014 Jul 17.

41.

Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis.

Dillingh MR, van den Blink B, Moerland M, van Dongen MG, Levi M, Kleinjan A, Wijsenbeek MS, Lupher ML Jr, Harper DM, Getsy JA, Hoogsteden HC, Burggraaf J.

Pulm Pharmacol Ther. 2013 Dec;26(6):672-6. doi: 10.1016/j.pupt.2013.01.008. Epub 2013 Feb 4.

PMID:
23380438
42.

"Tree in bud" attributable to organising pneumonia.

Bots EM, den Bakker MA, Wijsenbeek MS, van den Toorn LM, van den Blink B.

Thorax. 2013 Apr;68(4):399-400. doi: 10.1136/thoraxjnl-2012-202064. Epub 2012 Jul 27. No abstract available.

PMID:
22843557
43.

Serum biomarkers in idiopathic pulmonary fibrosis.

van den Blink B, Wijsenbeek MS, Hoogsteden HC.

Pulm Pharmacol Ther. 2010 Dec;23(6):515-20. doi: 10.1016/j.pupt.2010.08.001. Epub 2010 Aug 12. Review.

PMID:
20708704

Supplemental Content

Loading ...
Support Center